دورية أكاديمية
The use of 5-aminosalicylate for patients with Crohn's disease in a prospective European inception cohort with 5 years follow-up - an Epi-IBD study.
| العنوان: | The use of 5-aminosalicylate for patients with Crohn's disease in a prospective European inception cohort with 5 years follow-up - an Epi-IBD study. |
|---|---|
| المؤلفون: | Burisch J; Department of Gastroenterology, North Zealand University Hospital, Frederikssund, Denmark., Bergemalm D; Department of Gastroenterology, Örebro University, Örebro, Sweden., Halfvarson J; Department of Gastroenterology, Örebro University, Örebro, Sweden., Domislovic V; Department of Gastroenterology, Hepatology and Nutrition, 162072University Hospital Centre Zagreb, Zagreb, Croatia., Krznaric Z; Department of Gastroenterology, Hepatology and Nutrition, 162072University Hospital Centre Zagreb, Zagreb, Croatia.; School of Medicine, University of Zagreb, Zagreb, Croatia., Goldis A; Clinic of Gastroenterology, University of Medicine 'Victor Babes', Timisoara, Romania., Dahlerup JF; Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark., Oksanen P; Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere, Finland.; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland., Collin P; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland., de Castro L; Digestive Diseases Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), Vigo, Spain.; Department of Gastroenterology, Complexo Hospitalario Universitario de Vigo, Vigo, Spain., Hernandez V; Digestive Diseases Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), Vigo, Spain.; Department of Gastroenterology, Complexo Hospitalario Universitario de Vigo, Vigo, Spain., Turcan S; Department of Gastroenterology, State University of Medicine and Pharmacy of the Republic of Moldova, Chisinau, Republic of Moldova., Belousova E; Department of Gastroenterology, Moscow Regional Research Clinical Institute, Moscow, Russian Federation., D'Incà R; Department of Surgical, Oncological and Gastroenterological Sciences, University of Padua, Padova, Italy., Sartini A; UO Gastroenterologia ed Endoscopia digestiva, Hospital Morgagni Pierantoni, Forlì, Italy., Valpiani D; UO Gastroenterologia ed Endoscopia digestiva, Hospital Morgagni Pierantoni, Forlì, Italy., Giannotta M; Department of Gastroenterology, Azienda USL Toscana Centro, Florence, Italy., Misra R; IBD Department, Imperial College London, London, UK., Arebi N; IBD Department, Imperial College London, London, UK., Duricova D; IBD Clinical and Research Centre, ISCARE, Prague, Czech Republic.; Institute of Pharmacology, Charles University in Prague, Prague, Czech Republic., Bortlik M; IBD Clinical and Research Centre, ISCARE, Prague, Czech Republic.; Institute of Pharmacology, Charles University in Prague, Prague, Czech Republic., Gatt K; Division of Gastroenterology, 223089Mater Dei Hospital, Msida, Malta., Ellul P; Division of Gastroenterology, 223089Mater Dei Hospital, Msida, Malta., Pedersen N; Gastroenterology Department, Slagelse Hospital, Slagelse, Denmark., Kjeldsen J; Gastroenterology Department, Odense University Hospital, Odense, Denmark., Andersen KW; IRS-Center Soenderjylland, University Hospital of Southern Denmark, Aabenraa, Denmark., Andersen V; IRS-Center Soenderjylland, University Hospital of Southern Denmark, Aabenraa, Denmark.; Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark., Katsanos KH; Division of Gastroenterology, University Hospital and University of Ioannina, Greece., Christodoulou DK; Division of Gastroenterology, University Hospital and University of Ioannina, Greece., Sebastian S; Hull University Teaching Hospitals NHS Trust, Hull, UK.; Hull York Medical School, Hull, UK., Barros L; Department of Gastroenterology, Centro Hospitalar de São João EPE, Porto, Portugal., Magro F; Department of Gastroenterology, Centro Hospitalar de São João EPE, Porto, Portugal.; Department of Biomedicine, Porto University, Porto, Portugal., Midjord JM; Medical Department, The National Hospital of the Faroe Islands, Torshavn, Faroe Islands., Nielsen KR; Medical Department, The National Hospital of the Faroe Islands, Torshavn, Faroe Islands., Salupere R; Division of Gastroenterology, University of Tarty, Tartu, Estonia., Kievit HA; Department of Medicine, Herning Central Hospital, Herning, Denmark., Kiudelis G; Department of Gastroenterology, Lithuanian University of Health Sciences, Kaunas, Lithuania., Kupčinskas J; Department of Gastroenterology, Lithuanian University of Health Sciences, Kaunas, Lithuania.; Institute for Digestive Research, Lithuanian University of Health Sciences, Kaunas, Lithuania., Fumery M; Gastroenterology Unit, 26993Amiens University Hospital, Amiens, France., Gower-Rousseau C; Public Health, Epidemiology and Economic Health, Lille University and Hospital, Lille, France.; Institute for Translational Research in Inflammation (Infinite), Lille University, Lille, France., Kaimakliotis IP; Private practice, Nicosia, Cyprus., Schwartz D; Department of Gastroenterology and Liver Diseases, 26732Ben-Gurion University of the Negev, Beer Sheva, Israel., Odes S; Department of Internal Medicine, 26732Ben-Gurion University of the Negev, Beer Sheva, Israel., Lakatos L; Department of Internal Medicine, Csolnoky Ferenc Regional Hospital, Veszprem, Hungary., Lakatos PL; 1st Department of Medicine, Semmelweis University, Budapest, Hungary.; Division of Gastroenterology, McGill University Health Center, Montreal, Canada., Langholz E; Department of Gastroenterology, 53176Herlev Hospital, University of Copenhagen, Denmark., Munkholm P; Department of Gastroenterology, North Zealand University Hospital, Frederikssund, Denmark. |
| مؤلفون مشاركون: | Epi-IBD group |
| المصدر: | United European gastroenterology journal [United European Gastroenterol J] 2020 Oct; Vol. 8 (8), pp. 949-960. Date of Electronic Publication: 2020 Jul 26. |
| نوع المنشور: | Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley Country of Publication: England NLM ID: 101606807 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2050-6414 (Electronic) Linking ISSN: 20506406 NLM ISO Abbreviation: United European Gastroenterol J Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2021- : [London] : Wiley Original Publication: London : Sage Publications, [2013]- |
| مواضيع طبية MeSH: | Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use , Crohn Disease/*therapy , Mesalamine/*therapeutic use, Adult ; Biological Factors/therapeutic use ; Colectomy/statistics & numerical data ; Crohn Disease/diagnosis ; Crohn Disease/immunology ; Disease Progression ; Drug Therapy, Combination/methods ; Drug Therapy, Combination/statistics & numerical data ; Europe ; Female ; Follow-Up Studies ; Hospitalization/statistics & numerical data ; Humans ; Immunologic Factors/therapeutic use ; Maintenance Chemotherapy/methods ; Maintenance Chemotherapy/statistics & numerical data ; Male ; Middle Aged ; Prospective Studies ; Severity of Illness Index ; Treatment Outcome ; Young Adult |
| مستخلص: | Background: The lack of scientific evidence regarding the effectiveness of 5-aminosalicylate in patients with Crohn's disease is in sharp contrast to its widespread use in clinical practice. Aims: The aim of the study was to investigate the use of 5-aminosalicylate in patients with Crohn's disease as well as the disease course of a subgroup of patients who were treated with 5-aminosalicylate as maintenance monotherapy during the first year of disease. Methods: In a European community-based inception cohort, 488 patients with Crohn's disease were followed from the time of their diagnosis. Information on clinical data, demographics, disease activity, medical therapy and rates of surgery, cancers and deaths was collected prospectively. Patient management was left to the discretion of the treating gastroenterologists. Results: Overall, 292 (60%) patients with Crohn's disease received 5-aminosalicylate period during follow-up for a median duration of 28 months (interquartile range 6-60). Of these, 78 (16%) patients received 5-aminosalicylate monotherapy during the first year following diagnosis. Patients who received monotherapy with 5-aminosalicylate experienced a mild disease course with only nine (12%) who required hospitalization, surgery, or developed stricturing or penetrating disease, and most never needed more intensive therapy. The remaining 214 patients were treated with 5-aminosalicylate as the first maintenance drug although most eventually needed to step up to other treatments including immunomodulators (75 (35%)), biological therapy (49 (23%)) or surgery (38 (18%)). Conclusion: In this European community-based inception cohort of unselected Crohn's disease patients, 5-aminosalicylate was commonly used. A substantial group of these patients experienced a quiescent disease course without need of additional treatment during follow-up. Therefore, despite the controversy regarding the efficacy of 5-aminosalicylate in Crohn's disease, its use seems to result in a satisfying disease course for both patients and physicians. |
| References: | Gastroenterology. 2018 Feb;154(3):518-528.e15. (PMID: 29102619) Aliment Pharmacol Ther. 2016 Sep;44(5):482-94. (PMID: 27375210) Lancet. 1980 Mar 8;1(8167):514. (PMID: 6102236) Clin Gastroenterol Hepatol. 2020 May;18(5):1152-1160.e1. (PMID: 31419574) Dan Med J. 2014 Jan;61(1):B4778. (PMID: 24393595) Scand J Gastroenterol. 2016 Mar;51(3):304-13. (PMID: 26448101) Gastroenterology. 2010 Oct;139(4):1147-55. (PMID: 20637205) Inflamm Bowel Dis. 2014 Jan;20(1):60-8. (PMID: 24280875) Gut. 2014 Apr;63(4):588-97. (PMID: 23604131) Gut. 2019 Mar;68(3):423-433. (PMID: 29363534) Inflamm Bowel Dis. 2007 Aug;13(8):1009-15. (PMID: 17352386) J Crohns Colitis. 2019 Feb 1;13(2):198-208. (PMID: 30289522) J Crohns Colitis. 2011 Aug;5(4):342-9. (PMID: 21683305) Inflamm Bowel Dis. 2016 Nov;22(11):2665-2671. (PMID: 27753691) Philos Trans R Soc Lond B Biol Sci. 2011 Jun 27;366(1572):1905-12. (PMID: 21576148) Cochrane Database Syst Rev. 2016 Sep 28;9:CD003715. (PMID: 27681657) Dan Med Bull. 1999 Nov;46(5):400-15. (PMID: 10605619) Can J Gastroenterol. 2005 Sep;19 Suppl A:5A-36A. (PMID: 16151544) J Eval Clin Pract. 2008 Jun;14(3):453-9. (PMID: 18373568) Aliment Pharmacol Ther. 2014 Oct;40(8):930-7. (PMID: 25146487) J Crohns Colitis. 2020 Jan 1;14(1):4-22. (PMID: 31711158) Dan Med Bull. 1997 Jun;44(3):287-302. (PMID: 9233548) J Crohns Colitis. 2010 Nov;4(5):575-81. (PMID: 21122562) Gut. 2019 Dec;68(Suppl 3):s1-s106. (PMID: 31562236) Gut. 2014 Mar;63(3):423-32. (PMID: 23408350) Am J Gastroenterol. 2011 Apr;106(4):617-29. (PMID: 21407190) United European Gastroenterol J. 2015 Aug;3(4):371-80. (PMID: 26279846) Gut. 2017 Feb;66(2):362-381. (PMID: 27802156) Inflamm Bowel Dis. 2006 Apr;12(4):304-10. (PMID: 16633052) Dig Dis Sci. 2018 Oct;63(10):2555-2563. (PMID: 29959726) J Gastroenterol Hepatol. 2015 Sep;30(9):1346-53. (PMID: 25867770) J Crohns Colitis. 2013 May;7(4):322-37. (PMID: 23395397) Cochrane Database Syst Rev. 2016 Jul 03;7:CD008870. (PMID: 27372735) Scand J Gastroenterol. 1995 Jul;30(7):699-706. (PMID: 7481535) |
| فهرسة مساهمة: | Keywords: 5-aminosalicylates; Population-based cohort; disease course |
| المشرفين على المادة: | 0 (Anti-Inflammatory Agents, Non-Steroidal) 0 (Biological Factors) 0 (Immunologic Factors) 4Q81I59GXC (Mesalamine) |
| تواريخ الأحداث: | Date Created: 20200728 Date Completed: 20210712 Latest Revision: 20210712 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC7707880 |
| DOI: | 10.1177/2050640620945949 |
| PMID: | 32715989 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2050-6414 |
|---|---|
| DOI: | 10.1177/2050640620945949 |